-
Effects of Periconceptual Omega-3-Fatty Acid Supplementation on in Vitro Fertilization Success and Miscarriage Rates in Patients of a German Fertility Centre
Arasch Bareksei,
Gerd Hafner,
Sebastian Pfeiffer,
Kathrin Schlatterer
Issue:
Volume 5, Issue 5, September 2019
Pages:
62-66
Received:
6 September 2019
Accepted:
27 September 2019
Published:
10 October 2019
Abstract: Long-chain omega-3 fatty acids have been positively related with improvement of fertility in both women and men. Primary natural source of omega-3- fatty acids is seafood. As this also can bei the source of toxicants like f.e. lead, mercury and cadmium, reproductive benefits may be counteracted. Therefore, our approach was to supplement pharmaceutical grade omega-3-fatty acids in order to assess potential benefits of omega-3-fatty acids on modulation of IVF-success by dietary measures in a well-defined group of patients of a German Fertility Centre. A group of 52 IVF-patients with a history of at least two miscarriages or unsuccessful in vitro fertilization approaches received periconceptual omega-3-fatty acid supplementation for a time period of at least 3 weeks. The “historical” control group, consisting of 1109 patients without omega-3-fatty acid supplementation, was generated out of the Fertility Centre´s patient database. The same inclusion criteria (history of at least two miscarriages or unsuccessful in vitro fertilization approaches) were applied for both groups. Omega-3-fatty acid supplementation lead to significantly enhanced in vitro fertilization success rates as well as to reduction of miscarriage rates compared to patients of the control group. The results encourage to design further age-matched, double-blinded prospective studies in order to verify a positive influence of dietary intervention and lifestyle modification on fertility rates.
Abstract: Long-chain omega-3 fatty acids have been positively related with improvement of fertility in both women and men. Primary natural source of omega-3- fatty acids is seafood. As this also can bei the source of toxicants like f.e. lead, mercury and cadmium, reproductive benefits may be counteracted. Therefore, our approach was to supplement pharmaceuti...
Show More
-
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient
Stefania Federica De Mercanti,
Simona Rolla,
Manuela Matta,
Marco Iudicello,
Emanuele Franchin,
Marinella Clerico
Issue:
Volume 5, Issue 5, September 2019
Pages:
67-69
Received:
19 August 2019
Accepted:
4 September 2019
Published:
11 October 2019
Abstract: Alemtuzumab is a humanized anti-CD52 monoclonal antibody used for the treatment of high activity relapsing multiple sclerosis (R-MS). The most common adverse event is an infusion reaction due to cytokine-release. Autoimmunity can arise from months to years after treatment and encompasses Grave’s disease and thrombocytopenia. Recent reports of stroke, heart attack, and arterial dissection after alemtuzumab administration, in some cases within hours of infusion, led the European Medicines Agency’s (EMA's) Pharmacovigilance Risk Assessment Committee (PRAC) to a safety review of treatment with alemtuzumab. We report a D-Dimer increasing with suspected associated pulmonary embolism in an RMS patient after the first alemtuzumab administration. D-dimer test is not mandatory after alemtuzumab treatment, but its possible increase should warn the physician to select the patients with lower cardiovascular and thrombosis risk.
Abstract: Alemtuzumab is a humanized anti-CD52 monoclonal antibody used for the treatment of high activity relapsing multiple sclerosis (R-MS). The most common adverse event is an infusion reaction due to cytokine-release. Autoimmunity can arise from months to years after treatment and encompasses Grave’s disease and thrombocytopenia. Recent reports of strok...
Show More
-
Correlation Between Immunological Laboratory Status of Omega-3-Fatty-Acid-Supplemented Patients of a German Fertility Centre and Outcome of IVF-Treatment
Arasch Bareksei,
Gerd Hafner,
Sebastian Pfeiffer,
Kathrin Schlatterer
Issue:
Volume 5, Issue 5, September 2019
Pages:
70-79
Received:
6 September 2019
Accepted:
24 September 2019
Published:
17 October 2019
Abstract: A well-defined group of patients of a German Fertility Centre, all supplemented periconceptually with omega-3-fatty acids, was monitored for specific alterations in the immunological laboratory status in correlation with the outcome of in-vitro-fertilization-(IVF)-treatment. For 36 of 52 IVF-patients IVF-treatment was successful. Patients with IVF-success revealed statistically significant lower soluble interleukin-2-receptor concentrations than unsuccessfully treated patients. Decreased numbers of CD4-positive T-cells could be correlated with increased failure rates of IVF, increased numbers of regulatory T-cells on the other hand with significantly improved success rates. Six of the parameters analyzed (T-lymphocytes, T-helper cells, B-lymphocytes, CD4/CD8 ratio and both classes of regulatory T-cells) significantly more often were below the median of the respective distribution in patients without IVF-success than in successfully treated. These results offer the possibility of developing a simple prognostic measure for the outcome of an IVF-therapy by assessing these parameters in relation to the median of the respective distribution. With increasing numbers of parameters lying below the median, the probability of successful IVF-treatment is decreasing.
Abstract: A well-defined group of patients of a German Fertility Centre, all supplemented periconceptually with omega-3-fatty acids, was monitored for specific alterations in the immunological laboratory status in correlation with the outcome of in-vitro-fertilization-(IVF)-treatment. For 36 of 52 IVF-patients IVF-treatment was successful. Patients with IVF-...
Show More
-
Superiority of the Rapid Von Willebrand Factor (VWF) VWF:GPIbR and VWF:GPIbM Assays in Type 2A, 2B and 2M Von Willebrand Disease
Jan Jacques Michiels,
Petr Smejkal,
Katarzina Mayger,
Gary Moore,
Jan Blatny,
Miroslav Penka,
Ulrich Budde,
Zwi Berneman,
Inge Vangenechten,
Alain Gadisseur
Issue:
Volume 5, Issue 5, September 2019
Pages:
80-91
Received:
9 July 2019
Accepted:
30 August 2019
Published:
23 October 2019
Abstract: A complete set of rapid activity and classical von Willebrand factor (VWF) assays for Willebrand disease (VWD) diagnosis was used in the present study to characterize VWD type 1, 2A, 2B and 2M patients due to mutations in the A1, A2 and A3 domains. The VWF:RCo/VWF:Ag, VWF:GPIbM/VWF:Ag and VWF:GPIbR/VWF:Ag ratios at cuttt off value of 0.7 separated VWD type 1 and LowVWF from VWD type 2. The results from the Brno cohort of VWD 2A patients with the G1579R mutation in the A2 domain in sixteen affected member from five families and in one case with the G1609R in the A2 domain revealed that the VWF:GPIbM/VWF:Ag and VWF:GPIbR/VWF: Ag ratios are marked decreased (range 0.03-0.27) to a similar degree as compared to VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag ratios (range 0.03-0.27) due to the proteolytic loss of large and intermediate VWF multimers. The results in VWD 2B patients due to gain of ristocetin induced platelet agglutination (RIPA) function mutations R1306W, R1308C and R1341 in the A1 domain demonstrated that the ratios for VWF:GPIbM/VWF:Ag and VWF:GPIbR/VWF:Ag as compared to VWF:RCo/VWF:Ag ratio were markedly decreased in VWD 2B, whereas the VWF:GPIbM/VWF:Ag ratio was somewhat higher (range 0.32 to 0.36) in VWD 2M. VWD 2M patients due to loss of RIPA function mutation R1359K in the A1 domain are featured by decreased VWF ratios for WVF:RCo/Ag and VWF:GPIbR/Ag, but less decreased for the VWF:GPIbM/Ag ratio and normal VWF ratio for VWF:CB/Ag ratio the need to retain the VWF:CB assay to make a correct diagnosis of VWD 2M for its differentiation from VWD type 1. The G1415D mutation in the A1 domain is featured by decreased RIPA and decreased VWF:RCo/VWF:Ag ratio (VWD 2M) but normal values for VWF:CB/VWF:Ag, VWF:GPIbM/VWF:Ag and VWFGPIbR/VWF:Ag ratios consistent with VWD 2M. Double heterozygous P1266L/V1278I mutation in two patients and heterozygous E1292D/WT mutation in three patients in the A1 domain were diagnosed as VWD 2M or 1M associated with a secretion defect (SD). The Platelet Function Analyzer Closure Times (PFA-CT) are strongly prolonged in VWD 2A, 2B and 2M. and moderately prolonged between the upper limit of normal to 300 seconds in heterozygous mutated VWD type 1 patients.
Abstract: A complete set of rapid activity and classical von Willebrand factor (VWF) assays for Willebrand disease (VWD) diagnosis was used in the present study to characterize VWD type 1, 2A, 2B and 2M patients due to mutations in the A1, A2 and A3 domains. The VWF:RCo/VWF:Ag, VWF:GPIbM/VWF:Ag and VWF:GPIbR/VWF:Ag ratios at cuttt off value of 0.7 separated ...
Show More
